# Lexicon Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2023

- Company: [Lexicon Pharmaceuticals, Inc.](/companies/lxrx.md) (CIK 1062822)
- Form: 10-K
- Filed: 2024-03-25
- Accepted by EDGAR: Mar 25, 2024, 16:00 ET
- Period: 2023-12-31
- Accession: 0001062822-24-000008
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000008/lxrx-20231231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000008/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2023-01-01 to 2023-12-31 | $1.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2023-01-01 to 2023-12-31 | $85.0k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months, 2023-01-01 to 2023-12-31 | $58.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2023-01-01 to 2023-12-31 | $114.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2023-01-01 to 2023-12-31 | −$171.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2023-01-01 to 2023-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | −$177.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-31 | −$0.80 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-31 | −$0.80 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2023-01-01 to 2023-12-31 | 221,130,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | −$161.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2023-01-01 to 2023-12-31 | $470.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months, 2023-01-01 to 2023-12-31 | $824.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-12-31 | $22.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-12-31 | $176.5m | us-gaap:AssetsCurrent |
| Total assets | at 2023-12-31 | $229.4m | us-gaap:Assets |
| Current liabilities | at 2023-12-31 | $31.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-12-31 | $136.3m | us-gaap:Liabilities |
| Long-term debt | at 2023-12-31 | $99.5m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2023-12-31 | $93.1m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1062822/000106282224000008/lxrx-20231231.htm

Filed Mar 25, 2024.
Source: SEC EDGAR, the filing index for accession 0001062822-24-000008. Last ingested by Listed: Nov 5, 2026, 16:37 ET. No prices; not investment advice.